APOE Predicts Aβ but not Tau Alzheimer’s Pathology in Cognitively Normal Aging

By John C. Morris, Cathy Roe, C. Xiong, Anne M. Fagan, A. Goate, David M. Holtzman, Mark A. Mintun. Annals of Neurology, 2010

846 citations recorded by the source corpus.

To examine interactions of apolipoprotein E (APOE) genotype with age and with in vivo measures of preclinical Alzheimer disease (AD) in cognitively normal aging.

Subfields: Neurology, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/e02b89a6be3b5b2f9fb4338ad78638e6205ab28d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

In Physiology

In Psychiatry and Mental health

Citations in the corpus

The Centiloid Project: Standardizing Quantitative Amyloid Plaque Estimation by PET (2014, methodology): “…from 34 subjects under the age of 45 (31.5 ± 6.3 years; range 22-43) who were judged to be cognitively normal after a standard neuropsychological and clinical evaluation [7-9] This age range was used because it lends great certainty that the subject will be truly amyloid-negative [10; 11].”
Human apoE isoforms differentially regulate brain amyloid-β peptide clearance (2011, positive): “Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40).”
Alzheimer's disease risk genes and mechanisms of disease pathogenesis (2014, neutral): “also associated with cerebrospinal fluid Aβ42 and tau levels (15,16,43).”
Brain imaging in Alzheimer disease. (2012, background): “The prevalence of amyloid positivity is related closely to age and apolipoprotein-E allele status (Morris et al. 2010; Rowe et al. 2010).”
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics (2011, background): “If it can be assumed that APOE4 mediates its effects on AD by increasing amyloid-β deposition or reducing amyloid-β clearanc”
18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial (2010, background): “The prevalence of (11)C-PIB positivity in cognitively intact HVs increases from 6% in 50- to 59-yearolds up to 50% in subjects 80 years of age.(15) The clinical value of a positive scan in a cognitively intact subject remains to be determined by means of blinded prospective studies.”
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019, positive): “Longitudinal CSF, MRI and PET imaging studies of the preclinical phase of AD have established that APOE ε4 allele carriers develop enhanced cerebral amyloid deposition with age, do so at an earlier age and accumulate amyloid at a more rapid rate relative to noncarriers (Bussy et al., 2019; Grimmer e”
Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. (2012, background): “Further, apoE2-positive individuals rarely develop fibrillar Ab as defined by a positive amyloidimaging scan (Morris et al. 2010).”